PRME Prime Medicine, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
14:13
Aug 25
Aug 25
Author agrees with a parent post about healthcare leadership but only lists tickers without.
Author agrees with a parent post about healthcare leadership but only lists tickers without stating a position or forward call, so they are watch items.
LOW
18:25
Aug 19
Aug 19
Author acknowledges a biotech list with eye emojis but gives no explicit position or forward.
Author acknowledges a biotech list with eye emojis but gives no explicit position or forward call, so all tickers are indexed as watch.
LOW
15:17
Aug 19
Aug 19
Discloses long position in Prime Medicine.
Author discloses an active long position in Prime Medicine, expressing conviction in the trade following a recent price target upgrade.
MED
15:41
Aug 18
Aug 18
Author names ABCL as his favorite pick while viewing PRME and RXRX as promising but not.
Author names ABCL as his favorite pick while viewing PRME and RXRX as promising but not explicitly held, making ABCL a clear long and the others watch.
LOW
01:17
Aug 18
Aug 18
Author expresses hope that RXRX and PRME follow ABCL's trajectory but offers no position.
Author expresses hope that RXRX and PRME follow ABCL's trajectory but offers no position or explicit forward call, so both are watch.
LOW
19:15
Aug 17
Aug 17
Positive view on stock at current levels
Author expresses a positive directional view on the stock at current price levels.
MED
19:16
Aug 10
Aug 10
The author expresses a preference for these three biotech names over the parent's picks.
The author expresses a preference for these three biotech names over the parent's picks, but without stating a position or forward-looking call, so they are indexed as watch.
LOW
15:28
Jul 06
Jul 06
Author lists higher-risk tickers in a reply to a thematic research post.
Author lists higher-risk tickers in a reply to a thematic research post, but the reply lacks explicit position language or a forward call, so each ticker is indexed as watch.
LOW
23:03
Jun 23
Jun 23
Named as one of author's preferred health/bio sector picks in a multi-theme favorite-stocks.
Named as one of author's preferred health/bio sector picks in a multi-theme favorite-stocks list backed by personal research.
LOW
15:52
Jun 20
Jun 20
The author shares their favorite biotech stocks with AI-driven drug discovery and gene editing.
The author shares their favorite biotech stocks with AI-driven drug discovery and gene editing platforms but frames them as personal favorites without an explicit forward-looking position or trade call.
07:34
Jun 20
Jun 20
Author lists favorite stocks per sector and explicitly states IREN, HIMS.
Author lists favorite stocks per sector and explicitly states IREN, HIMS, and ONDS are top picks for 2026, with ownership of most names, indicating a long bias across the basket.
LOW
07:33
Jun 20
Jun 20
Author lists favorite stocks per sector with IREN, HIMS, and ONDS as top 2026 picks.
Author lists favorite stocks per sector with IREN, HIMS, and ONDS as top 2026 picks, but only IREN and HIMS are explicitly owned as current long positions while the rest are watchlist mentions.
LOW
10:23
Jun 03
Jun 03
The author lists favorite stocks by sector as a thematic watchlist without explicitly stating.
The author lists favorite stocks by sector as a thematic watchlist without explicitly stating current positions or forward calls, so each ticker is indexed as watch.
LOW
10:18
Jun 03
Jun 03
The author lists favorite stocks per sector as a thematic watchlist without explicitly stating.
The author lists favorite stocks per sector as a thematic watchlist without explicitly stating current positions or forward calls, so all tickers are indexed as watch.
LOW
22:08
Apr 27
Apr 27
Long $PRME — speaker self-RTs that it 'might be the stock to buy for 2026,' citing its Prime.
Long $PRME — speaker self-RTs that it 'might be the stock to buy for 2026,' citing its Prime Editing gene-editing platform ('precise search-and-replace') as the thesis.
MED
13:25
Apr 27
Apr 27
Speaker calls $PRME 'might be the stock to buy for 2026' with detailed thesis.
Speaker calls $PRME 'might be the stock to buy for 2026' with detailed thesis: best Prime Editing platform, high-value in-vivo liver programs (Wilson's Disease PM577).
MED
00:28
Mar 16
Mar 16
PRME cited as pharma-disruption biotech
Author co-mentions PRME alongside peers as a biotech company with potential to disrupt the pharma industry; no directional commitment made.
LOW
About PRME Analyst Coverage
Buzzberg tracks PRME (Prime Medicine, Inc.) across 4 sources. 3 bullish vs 0 bearish calls from 4 analysts. Sentiment: predominantly bullish (18%). 17 total trade ideas tracked. Latest voices: rosannainvests, caesarcapitalz, moninvestor.